{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '6.2.12', 'Vital signs', '6.2.12.1', 'Pulse and blood pressure', 'Blood pressure and pulse rate will be measured using an automated blood pressure cuff/heart', 'monitor. For timings of assessments refer to Sections 5.2 and 5.3.', '6.2.12.2 Body temperature', 'Body temperature will be measured in degrees Celsius using an automated thermometer. For', 'timings of assessments refer to Sections 5.2 and 5.3.', '6.2.13', 'Bone marrow or blood cytogenetic analysis', 'Bone marrow or blood cytogenetic analysis may be performed according to standard', 'hematological practice for patients with prolonged hematological toxicities as defined in', 'Section 8.2.7. Bone marrow analysis should include an aspirate for cellular morphology,', 'cytogenetic analysis and flow cytometry, and a core biopsy for bone marrow cellularity. If it', 'is not possible to conduct cytogenetic analysis or flow cytometry on the bone marrow aspirate,', 'then attempts should be made to carry out the tests on a blood sample. If findings are', 'consistent with MDS/AML, study drug should be discontinued and a full description of', 'findings should be submitted with an SAE report by the investigator to AstraZeneca Patient', 'Safety for documentation on the Patient Safety database. Presence or absence of blood', 'cytogenetic abnormalities and flow cytometry will be documented on the clinical database.', '6.3', 'Exploratory biomarkers', 'This study will incorporate a number of exploratory biomarkers. Given our rapidly evolving', 'understanding of prostate cancer pathobiology and genetics, it is impossible to prospectively', 'define all the relevant biomarkers for the patient population enrolled on this study. All samples', 'will be collected at the timepoints indicated in Sections 5.2 and 5.3 of the protocol. Details', 'regarding the collection, processing, shipping and storage of samples for exploratory research', 'will be described in the Laboratory Manual. Examples of the studies to be conducted may', 'include, but will not be limited to those described below. Additional studies aimed at', 'understanding response and resistance to the study drugs may be added as new information', 'becomes available.', '6.3.1', 'DNA Damage Repair Gene Status', 'All patients will undergo targeted next-generation sequencing in order to evaluate for the', 'presence of a DDR gene alteration at baseline. This will be accomplished using the UW-', 'OncoPlex platform, which has been validated for use with tumor tissue derived DNA and cell-', 'free tumor DNA (ctDNA)[97]. The preferred sample for sequencing is one taken following', 'the completion of the most recent prior line of therapy. Samples taken at this time reflect the', 'current DDR status of the tumor and are considered clinically most relevant. A fresh', 'metastatic biopsy is therefore preferred for UW-OncoPlex testing. If patient refuses metastatic', 'biopsy or it is felt that this cannot be conducted safely, the most recent tissue sample may be', 'used, or if a patient has a PSA >20 ng/mL, a plasma sample may be used for ctDNA', '55(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', 'sequencing. Optional biopsies will be requested at timepoints indicated in Sections 5.2 and', '5.3.', 'Note: If prior to enrolling, a patient has already had their tumor sequenced using a clinical', 'grade next-generation sequencing assays (e.g. FoundationOne, Caris, etc), these results may', 'be used for determining baseline DDR gene mutational status. Tumor tissue should still be', 'obtained as outlined above to confirm DDR status using UW-OncoPlex, however.', '6.3.2', 'Protein expression studies', 'Protein expression studies will be conducted on circulating tumor cells (CTCs) and/or tumor', 'tissue using immunofluorescence (IF) and immunohistochemistry (IHC), respectively.', 'Expression of full-length AR (AR-FL), AR splice variants (AR-Vs), y-H2AX as well as', 'potentially other proteins will be assessed. IHC will be will be performed using commercially', 'available antibodies and standard lab techniques. CTCs for protein studies will be isolated', 'using the RareCyte platform, which involves density-based enrichment followed IF staining', 'and digital microscopy[98].', '6.3.3', 'Transcript profiling studies', 'Transcript profiling studies will be conducted on circulating tumor cells (CTCs) and/or tumor', 'tissue. Transcript profiling on tumor tissue will be performed using RNA-seq, qRT-PCR or', 'other gene expression profiling methods as appropriate (e.g. NanoString), and will follow', 'standard lab techniques. Adna Test will be used to isolate CTCs for transcript expression', 'studies[45]. AdnaTest isolates CTCs using antibody coated magnetic beads, which are', 'designed to select populations of prostate cancer cells, and is suitable for transcript profiling', 'studies. Blood samples will be processed using AdnaTest and used for multiplexed qRT-PCR', 'studies.', '6.3.4', 'Tissue and Serum Androgen Levels', 'Tissue and serum androgens (e.g. T and DHT) and hormonal substrates (e.g. DHEA-S) will be', 'determined in serum and metastatic biopsy specimens using liquid chromatography-mass', 'spectrometry (LC/MS) according to previously described methods[99-102].', '6.4', 'Patient reported outcomes (PRO)', 'The FACT-P and IIEF quality of life questionnaires will be administered periodically', 'throughout the duration of the study (Appendix 4). Patients will be provided with blank', 'questionnaires and encouraged to complete these at home prior to scheduled clinic visits as', 'outlined in Sections 5.2 and 5.3. These may also be completed in the clinic if preferred by the', 'patient. If completed at home, questionnaires must be completed within the time windows', 'indicated in Sections 5.2 and 5.3. Scoring of these surveys will be performed as previously', 'described [103, 104].', '56(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}